In all due respect these scenarios are ridiculous. The dilution is needed for burn rate, trials, everything pretty much. An up list , let alone an uplist from strength, is not possible from our current financial situation. The plan was to ipo from shelf however that's absurd I mean literally absurd from this pps! Horrible for all shareholders including management who have shares. There was never a plan to tap shelf and raise at 1.44. Nasdaq at 1.44 with no funds just seems silly, I'd assume committee would feel a dlist would be in cards with continued dilution guaranteed. They need to ipo to raise and not from 1.44 lol
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links